Cargando…
Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma
BACKGROUND: Patients with regional lymph node recurrence after radical resection of esophageal cancer have poor therapeutic outcomes. Currently, there is no standard treatment for regional lymph node recurrence, and its prognostic risk factors are not well-understood. This study retrospectively anal...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749665/ https://www.ncbi.nlm.nih.gov/pubmed/31533757 http://dx.doi.org/10.1186/s13014-019-1377-y |
_version_ | 1783452324443717632 |
---|---|
author | Chen, Jie Yin, Wenming Yao, Hui Gu, Wendong |
author_facet | Chen, Jie Yin, Wenming Yao, Hui Gu, Wendong |
author_sort | Chen, Jie |
collection | PubMed |
description | BACKGROUND: Patients with regional lymph node recurrence after radical resection of esophageal cancer have poor therapeutic outcomes. Currently, there is no standard treatment for regional lymph node recurrence, and its prognostic risk factors are not well-understood. This study retrospectively analyzed 83 patients with postoperative regional lymph node recurrence after radical resection of esophageal squamous cell carcinoma. The aim was to evaluate the clinical efficacy and prognostic factors of salvage radiotherapy with or without chemotherapy in these patients. METHODS: The survival and prognostic factors of 83 patients with esophageal squamous cell carcinoma with regional lymph node recurrence after radical surgery were retrospectively analyzed. All patients underwent radiotherapy, of which 74 patients received volumetric modulated arc therapy (VMAT), 9 patients received three-dimensional conformal radiation therapy (3DCRT), administered using a conventional segmentation protocol with a dose distribution range of 50.4–66.2Gy (median dose of 60Gy). In total, 41 patients received radiotherapy alone, 42 received radiotherapy combined with chemotherapy, and the concurrent chemotherapy regimen was mainly composed of either platinum or fluorouracil monotherapy, except for 4 patients who were given 5-fluorouracil plus platinum (FP) or paclitaxel plus platinum (TP). RESULTS: The median follow-up time was 24 (range, 9–75) months. The overall survival (OS) rates at 1 year, 2 years, 3 years, and 5 years were 83.0, 57.1, 40.1, and 35.1%, respectively. The median overall survival (OS) time was 18 (range, 5–75) months. The 3-year survival rate was 47.5% in patients with radiation alone and 41.9% in patients receiving concurrent chemoradiotherapy(p = 0.570), while the response rate (CR + PR) in those two groups was 73.2 and 91.4%, respectively. By multivariate analysis of OS, age (worse in younger patients, p = 0.034) was found to be significantly associated with disease prognosis. The commonly toxicities were esophagitis, neutropenia and anemia. 18% patients experienced grade 3 toxicity and no treatment-related death occurred. CONCLUSIONS: These results of this retrospective analysis suggest that radiotherapy with or without chemotherapy is an effective and feasible salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma. |
format | Online Article Text |
id | pubmed-6749665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67496652019-09-23 Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma Chen, Jie Yin, Wenming Yao, Hui Gu, Wendong Radiat Oncol Research BACKGROUND: Patients with regional lymph node recurrence after radical resection of esophageal cancer have poor therapeutic outcomes. Currently, there is no standard treatment for regional lymph node recurrence, and its prognostic risk factors are not well-understood. This study retrospectively analyzed 83 patients with postoperative regional lymph node recurrence after radical resection of esophageal squamous cell carcinoma. The aim was to evaluate the clinical efficacy and prognostic factors of salvage radiotherapy with or without chemotherapy in these patients. METHODS: The survival and prognostic factors of 83 patients with esophageal squamous cell carcinoma with regional lymph node recurrence after radical surgery were retrospectively analyzed. All patients underwent radiotherapy, of which 74 patients received volumetric modulated arc therapy (VMAT), 9 patients received three-dimensional conformal radiation therapy (3DCRT), administered using a conventional segmentation protocol with a dose distribution range of 50.4–66.2Gy (median dose of 60Gy). In total, 41 patients received radiotherapy alone, 42 received radiotherapy combined with chemotherapy, and the concurrent chemotherapy regimen was mainly composed of either platinum or fluorouracil monotherapy, except for 4 patients who were given 5-fluorouracil plus platinum (FP) or paclitaxel plus platinum (TP). RESULTS: The median follow-up time was 24 (range, 9–75) months. The overall survival (OS) rates at 1 year, 2 years, 3 years, and 5 years were 83.0, 57.1, 40.1, and 35.1%, respectively. The median overall survival (OS) time was 18 (range, 5–75) months. The 3-year survival rate was 47.5% in patients with radiation alone and 41.9% in patients receiving concurrent chemoradiotherapy(p = 0.570), while the response rate (CR + PR) in those two groups was 73.2 and 91.4%, respectively. By multivariate analysis of OS, age (worse in younger patients, p = 0.034) was found to be significantly associated with disease prognosis. The commonly toxicities were esophagitis, neutropenia and anemia. 18% patients experienced grade 3 toxicity and no treatment-related death occurred. CONCLUSIONS: These results of this retrospective analysis suggest that radiotherapy with or without chemotherapy is an effective and feasible salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma. BioMed Central 2019-09-18 /pmc/articles/PMC6749665/ /pubmed/31533757 http://dx.doi.org/10.1186/s13014-019-1377-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Chen, Jie Yin, Wenming Yao, Hui Gu, Wendong Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma |
title | Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma |
title_full | Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma |
title_fullStr | Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma |
title_full_unstemmed | Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma |
title_short | Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma |
title_sort | salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749665/ https://www.ncbi.nlm.nih.gov/pubmed/31533757 http://dx.doi.org/10.1186/s13014-019-1377-y |
work_keys_str_mv | AT chenjie salvagetreatmentforlymphnoderecurrenceafterradicalresectionofesophagealsquamouscellcarcinoma AT yinwenming salvagetreatmentforlymphnoderecurrenceafterradicalresectionofesophagealsquamouscellcarcinoma AT yaohui salvagetreatmentforlymphnoderecurrenceafterradicalresectionofesophagealsquamouscellcarcinoma AT guwendong salvagetreatmentforlymphnoderecurrenceafterradicalresectionofesophagealsquamouscellcarcinoma |